Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154476 | 0.74 | TSHR (0.37) | LMNASLC6A6CYP2C19BLMTSHR | |
| SCHEMBL20742048 | 0.73 | TSHR (0.43) | TSHR | |
| SCHEMBL8420074 | 0.72 | HTT (0.33) | LMNATSHR | |
| SCHEMBL1794070 | 0.71 | TSHR (0.41) | TSHR | |
| Cadaverine Tartrate SCHEMBL1154468 | 0.70 | BLM (0.64) | LMNASLC6A6CYP2C19BLMTSHR | |
| SCHEMBL9437852 | 0.70 | TSHR (0.39) | TSHR | |
| SCHEMBL3634910 | 0.70 | TSHR (0.39) | TSHR | |
| Benzene SCHEMBL9474100 | 0.68 | TSHR (0.38) | TSHR | |
| SCHEMBL1154473 | 0.68 | LMNA (0.37) | LMNASLC6A6CYP2C19BLM | |
| Cadaverine Tartrate SCHEMBL342524 | 0.65 | TSHR (0.67) | LMNABLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942877-A1 | ORGANOLEPTICALLY ACCEPTABLE IBUPROFEN ORAL DOSAGE FORMULATIONS, METHODS OF MAKING AND USING THE SAME | Teikoku Pharma USA, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| WO-2007055887-A1 | ORGANOLEPTICALLY ACCEPTABLE IBUPROFEN ORAL DOSAGE FORMULATIONS, METHODS OF MAKING AND USING THE SAME | TEIKOKU PHARMA USA, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070098789-A1 | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same | TEIKOKU PHARMA USA, INC. | 2007-05-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098789-A1 | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same | CYP2D6, CYP2A6, CYP2C9 | LMNA 3815/4885SLC6A6 1981/4885CYP2C19 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.